Variability in melanoma metalloproteinase expression profiling

Journal of Biomolecular Techniques

Volumn 21, Issue 4, 2010, Pages 194-204

  Giricz, Orsi ^a,b   Lauer, Janelle L ^c,d   Fields, Gregg B ^c  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

ADAM; MMP; Tissue

Indexed keywords

ADAM PROTEIN; ADAM15 PROTEIN; ADAMTS1 PROTEIN; COMPLEMENTARY DNA; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 15; MESSENGER RNA; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL; METASTASIS; MOLECULE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE CULTURE; TUMOR CELL;

ADAM PROTEINS; CELL LINE; CELLS, CULTURED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES; MELANOMA; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 78650143782     PISSN: 15240215     EISSN: 19434731     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Morton DL, Essner R, Kirkwood JM, Wollman RC. Malignant melanoma. In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS (eds): Cancer Medicine, 6th ed. Philadelpha, PA, USA: B.C. Decker, 2003.
2. Lucas R, McMichael T, Smith W, Armstrong B. Solar ultraviolet radiation: global burden of disease from solar ultraviolet radiation. World Health Organization: Environmental Burden of Disease Series, 2006.
3. Berwick M, Halpern A. Melanoma epidemiology. Curr Opin Oncol 1997;9:178-182.
4. Clark WH, Elder Jr. DE, Guerry D, Epstein MN, Greene MH, van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147-1165. (Pubitemid 15128121)
5. Bar-Eli M. Molecular mechanisms of melanoma metastasis. J Cell Physiol 1997;173:275-278.
6. Welch DR, Goldberg SF. Molecular mechanisms controlling human melanoma progression and metastasis. Pathobiology 1997;65:311-330. (Pubitemid 28041158)
7. Macgregor PF, Squire JA. Application of microarrays to the analysis of gene expression in cancer. Clin Chem 2002;48:1170-1177. (Pubitemid 34809821)
8. Rocks N, Paulissen G, El Hour M, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 2008;90:369-379. (Pubitemid 351172571)
9. Fridman R. Metalloproteinases and cancer. Cancer Metastasis Rev 2006;25:7-8.
10. White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 2003;15:598-606. (Pubitemid 37176969)
11. Schwettmann L, Tschesche H. Cloning and expression in Pichia pastoris of metalloprotease domain ofADAM9 catalytically active against fibronectin. Protein Exp Purif 2001;21:65-70. (Pubitemid 32614497)
12. Millichip MI, Dallas DJ, Wu E, Dale S, McKie N. The metallodisintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun 1998;245:594-598. (Pubitemid 28418550)
13. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J 2005;386:15-27.
14. Apte SS. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem 2009;284:31493-31497.
15. Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006;312:608-622. (Pubitemid 43290337)
16. Gallagher PG, Bao Y, Prorock A, et al. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res 2005;65:4134-4146. (Pubitemid 40775651)
17. Zigrino P, Mauch C, Fox JW, Nischt R. ADAM-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer 2005;116:853-859. (Pubitemid 41209190)
18. Hoek KS. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 2007;20:466-484. (Pubitemid 47568833)
19. Masters JRW, Palson B. Cancer Cell Lines Part Ied. Dorchedt, The Netherlands: Kluwer Academic Publishers, 1999.
20. Tuschl G, Mueller SO. Effects of cell culture conditions on primary rat hepatocytes- cell morphology and differential gene expression. Toxicology 2006;218:205-215. (Pubitemid 41821351)
21. Masramon L, Vendrell E, Tarafa G, et al. Genetic instability and divergence of clonal populations in colon cancer cells in vitro. J Cell Sci 2006;119:1477-1182.
22. Van den Oord JJ, Sarasin A, Winnepenninckx V, Spatz A. Expression profiling of melanoma cell lines: in search of a progression-related molecular signature. Future Oncol 2007;3:609-611.
23. Hsu M-Y, Elder DE, Herlyn M. Melanoma: the Wistar melanoma (WM) cell lines. In Masters JRW, Palsson B (eds): Human Cell Culture, vol I, Cancer Cell Lines Part 1 Dordrecht, The Netherlands: Kluwer Academic Publishers, 1999;259-274.
24. Giricz O, Lauer-Fields JL, Fields GB. The normalization of gene expression data in melanoma: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR. Anal Biochem 2008;380:137-139.
25. Marshall OJ. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinformatics 2004;20:2471-2472. (Pubitemid 39429922)
26. Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, López-Otín C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 2002;283:49-62. (Pubitemid 34178509)
27. Puxeddu I, Pang YY, Harvey A, et al. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol 2008;121:1400-1406.
28. Rosendahl MS, Ko SC, Long DL, et al. Identification and characterization of a pro-tumor necrosis factor-α-processing enzyme from the ADAM family of zinc metalloproteases. J Biol Chem 1997;272:24588-24593. (Pubitemid 27418673)
29. Lunn CA, Fan X, Dalie B, et al. Purification of ADAM 10 from bovine spleen as a TNFα convertase. FEBS Lett 1997;400:333-335. (Pubitemid 27039378)
30. Sanderson MP, Erickson SN, Gough PJ, et al. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J Biol Chem 2005;280:1826-1837.
31. Moss ML, Bomar M, Liu Q, et al. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem 2007;282:35712-35721. (Pubitemid 350277116)
32. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM. Cysteine-rich domain of human ADAM 12 (Meltrin α) supports tumor cell adhesion. Am J Pathol 1999;154:1489-1501. (Pubitemid 29226444)
33. Iba K, Albrechtsen R, Gilpin B, et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading. J Cell Biol 2000;149:1143-1156.
34. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323-51330. (Pubitemid 40017878)
35. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:621-628. (Pubitemid 46563436)
36. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Röcken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2004;131:41-48.
37. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Röcken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 2005;26:17-24.
38. Trochon-Joseph V, Martel-Renoir D, Mir LM, et al. Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res 2004;64:2062-2069. (Pubitemid 38339454)
39. Black RA, Rauch CT, Kozlosky et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature 1997;385:729-733. (Pubitemid 27098094)
40. Kenny PA. TACE: a new target in epidermal growth factor receptor dependent tumors. Differentiation 2007;75:800-808. (Pubitemid 350086166)
41. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004;44:195-217. (Pubitemid 38263839)
42. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769-779. (Pubitemid 38282960)
43. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:9-15.
44. Giambernardi TA, Sakaguchi AY, Gluhak J, et al. Neutrophil collagenase (MMP-8) is expressed during early development in neural crest cells as well as in adult melanoma cells. Matrix Biol 2001;20:577-587. (Pubitemid 33109105)
45. Palavalli LH, Prickett TD, Wunderlich JR, et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genetics 2009;241:518-520.
46. Zigrino P, Kuhn I, Bäuerle T, et al. Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Invest Dermatol 2009;129:2686-2693.
47. Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol 2008;29:377-385.
48. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kähäri V-M, Pyrhönen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002;97:432-438. (Pubitemid 34027800)
49. Blackburn JS, Rhodes CH, Coon CI, Brinckerhoff CE. RNA interference inhibition by matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res 2007;67:10849-10858. (Pubitemid 350145914)
50. Iida J, McCarthy JB. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-β. Melanoma Res 2007;17:205-213. (Pubitemid 47067078)
51. Kondratiev S, Gnepp DR, Yakirevich E, et al. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. Human Pathol 2008;39:337-343. (Pubitemid 351186686)
52. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997;15:519-526. (Pubitemid 27190026)
53. Borden P, Heller RA. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr 1997;7:159-178. (Pubitemid 27148904)
54. Westermarck J, Kahari V-M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781-792. (Pubitemid 29220691)
55. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000;291:113-135.
56. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1149. (Pubitemid 30123793)
57. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kDa type IV collagenase) expression occurs in the early stage of human melanocytic tumor progression and may have prognostic value. J Pathol 1996:180:283-289. (Pubitemid 26393677)
58. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998;186:51-58. (Pubitemid 28407488)
59. Bodey B, Bodey JB, Siegel SE, Kaiser HF. Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interactions in invasion and metastasis. In Vivo 2001;15:57-64. (Pubitemid 32248998)
60. Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol 2002;197:179-187. (Pubitemid 34567605)
61. Hofmann UB, Westphal JR, van Muijen GNP, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000;115:337-344.
62. Pereira AM, Strasberg-Rieber M, Rieber M. Invasion-associated MMP-2 and MMP-9 are up-regulated intracellularly in concert with apoptosis linked to melanoma cell detachment. Clin Exp Metastasis 2005;22:285-295. (Pubitemid 41374285)
63. Levi E, Fridman R, Miao H-Q, Ma Y-S, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996;93:7069-7074. (Pubitemid 26243503)
64. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174. (Pubitemid 37328786)
65. Dean RA, Overall CM. Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQTM labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 2007;6:611-623. (Pubitemid 46630094)
66. Okada A, Tomasetto C, Lutz Y, Bellocq J-P, Rio M-C, Basset P. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Biol 1997;137:67-77. (Pubitemid 27167296)
67. Pulyaeva H, Bueno J, Polette M, et al. MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis 1997;15:111-120. (Pubitemid 27157813)
68. Gilles C, Polette M, Piette J, et al. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 1996;65:209-213. (Pubitemid 26051683)
69. Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006;6:52.
70. D'Ortho M-P, Will H, Atkinson S, et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997;250:751-757. (Pubitemid 28022492)
71. Butler GS, Dean RA, Tam EM, Overall CM. Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of a membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Mol Cell Biol 2008;28:4896-4914.
72. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-65. (Pubitemid 24216953)
73. Knäuper V, Will H, Lopez-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 1996;271:17124-17131. (Pubitemid 26244262)
74. Nakada M, Nakamura H, Ikeda E, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999;154:417-428. (Pubitemid 29094092)
75. Davidson B, Goldberg I, Berner A, et al. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 2001;115:517-524. (Pubitemid 32275943)
76. Kitagawa Y, Kunimi K, Uchibayashi T, Sato H, Namiki M. Expression of messenger RNAs for membrane-type 1, 2, and 3 matrix metalloproteinases in human renal cell carcinomas. J Urol 1999;162:905-909. (Pubitemid 29436915)
77. Ueno H, Nakamura H, Inoue M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997;57:2055-2060. (Pubitemid 27209741)
78. Lafleur MA, Drew AF, de Sousa EL, et al. Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13. Int J Cancer 2005;114:544-554. (Pubitemid 40349612)
79. Ohnishi Y, Tajima S, Ishibashi A. Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells. Eur J Dermatol 2001;11:420-423. (Pubitemid 32801337)
80. Hotary KB, Yana I, Sabeh F, et al. Matrix metalloproteinases regulate fibrin-invasive activity via MT1-MMP-dependent and independent processes. J Exp Med 2002;195:295-308. (Pubitemid 34461487)
81. Morrison CJ, Butler GS, Bigg HF, Roberts CR, Soloway PD, Overall CM. Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. J Biol Chem 2001;276:47402-47410. (Pubitemid 37373122)
82. Benbow U, Schoenermark MP, Mitchell TI, et al. A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen. J Biol Chem 1999;274:25371-25378.
83. Li L, Dragulev B, Zigrino P, Mauch C, Fox JW. The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo. Int J Cancer 2009;125:1796-1804.
84. Alberts B. Cells in Their Social Context Molecular Biology of the Cell, 5th ed. New York, NY, USA: Garland Publishing, 2007.
85. Connolly JL, Schnitt SJ, Wang HH, Dvorak AM, Dvorak HF. Principles of cancer pathology. In Kufe DW, Pollock RE, Weichselbaum RR, Bast Jr, RC, Gansler TS (eds): Cancer Medicine, 6th ed. Philadelpha, PA, USA: B.C. Decker, 2003.
86. Mueller MM, Fusenig NE. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002;70:486-497. (Pubitemid 36194314)
87. Fini ME, Girard MT. The pattern of metalloproteinase expression by corneal fibroblasts is altered by passage in cell culture. J Cell Sci 1990;97:373-383. (Pubitemid 20361416)
88. Arkell J, Jackson CJ. Constitutive secretion of MMP9 by early-passage cultured human endothelial cells. Cell Biochem Function 2003;21:381-386. (Pubitemid 37456346)
89. Reunanen N, Li S-P, Ahonene M, Foschi M, Han J, Kähäri V-M. Activation of p38a mitogen-activated protein kinase enhances collagenase-1 (MMP-1) and stromelysin-1 (MMP-3) expresssion by mRNA stabilization. J Biol Chem 2002;277:32360-32368. (Pubitemid 34969054)
90. Reuben PM, Cheung HS. Regulation of matrix metalloproteinase (MMP) gene expression by protein kinases. Front Biosci 2006;11:1199-1215. (Pubitemid 43253412)
91. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007;26:587-596. (Pubitemid 350180394)
92. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008;29:290-308.
93. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodeling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-770. (Pubitemid 46582040)
94. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009;9:20.